Jasper Therapeutics, INC 8-K filings

Jasper Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders, confirming the election of directors and ratification of its independent auditor.

Jasper Therapeutics confirms the terms of contingent value rights (CVRs) issued in connection with its acquisition of Kira Pharmaceuticals, detailing potential milestone payments tied to FDA approval.

Jasper Therapeutics has completed its acquisition of Kira Pharmaceuticals and secured $132 million in private placement financing to advance a combined pipeline of immunology-focused therapies.

Jasper Therapeutics received a notice from Nasdaq indicating its common stock has closed below the $1.00 minimum bid price requirement, with a 180-day period to regain compliance.

Jasper Therapeutics is initiating a comprehensive review of strategic alternatives to maximize shareholder value, including potential asset sales, mergers, or an orderly wind-down.

Jasper Therapeutics announces the resignation of director Christian Nolet and the appointment of Dr. Svetlana Lucas to the Audit Committee.

Jasper Therapeutics announced its fourth quarter and full-year 2025 financial results, alongside positive clinical data for briquilimab in chronic urticaria and asthma, with future study progress contingent on capital availability.

Jasper Therapeutics reported rapid, durable responses and favorable safety for briquilimab in chronic urticaria, enabling dose selection and a planned Phase 2b CSU study in the second half of 2026.

Jasper Therapeutics announced the appointment of Jeet Mahal as its new Chief Executive Officer and Thomas Wiggans as Executive Chairperson, effective January 5, 2026, signaling a strategic leadership transition for its next phase of clinical growth.

Jasper Therapeutics announced positive preliminary Phase 1b data for briquilimab in allergic asthma and concluded its internal investigation into anomalous BEACON study results, attributing them to patient selection issues.

Jasper Therapeutics reported Q3 2025 financial results, revealing an ongoing investigation into anomalous clinical trial data and a delay in its Phase 2b study, despite extending its cash runway.

Jasper Therapeutics announced the pricing of a $30 million public offering of common stock and warrants, while also providing an update on its investigation into confounded efficacy results from its BEACON study.

Jasper Therapeutics reported its second quarter 2025 financial results, announced a corporate restructuring with a 50% workforce reduction, and is investigating an atypical response in a key clinical trial cohort.

Jasper Therapeutics is undergoing a significant corporate reorganization, including a 50% workforce reduction and the halting of non-core clinical and preclinical programs, to extend its cash runway and focus solely on briquilimab development for chronic urticaria.

Jasper Therapeutics announced updated clinical data for its briquilimab therapy in chronic spontaneous urticaria, showing strong efficacy in some cohorts but revealing a confounding drug product lot issue that led to halting its asthma and SCID programs and delaying its Phase 2b CSU study.

Jasper Therapeutics, Inc. announced that its stockholders approved all four proposals, including the election of three Class I directors and the ratification of its independent auditor, at the 2025 Annual Meeting held on July 3, 2025.

Jasper Therapeutics announced positive top-line data from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study of briquilimab for chronic inducible urticaria, showing high complete response rates and a favorable safety profile.

Jasper Therapeutics announced its first quarter 2025 financial results, highlighting progress in its briquilimab clinical programs for mast cell diseases.

Jasper Therapeutics has entered into a sales agreement with Jefferies for potential stock sales up to $100 million and terminated its previous agreement with Cantor Fitzgerald.

Jasper Therapeutics announces positive clinical data from its briquilimab studies and reports its financial results for the fourth quarter and full year 2024.

Jasper Therapeutics reported positive preliminary data from its BEACON Phase 1b/2a study of briquilimab, showing rapid and durable clinical responses in patients with chronic spontaneous urticaria.

Jasper Therapeutics reported positive initial data from its SPOTLIGHT study in chronic inducible urticaria, along with third quarter financial results and a corporate update.

Jasper Therapeutics reported that 93% of participants in their SPOTLIGHT study achieved a clinical response to briquilimab for chronic inducible urticaria, with 83% of the 120mg cohort achieving a complete response.

Jasper Therapeutics has appointed Svetlana Lucas to its Board of Directors, effective June 18, 2024, following the resignation of Anna French.

Jasper Therapeutics has amended employment agreements for its CEO, CFO, COO, and CMO, and approved new equity incentive and employee stock purchase plans.

Jasper Therapeutics announced its fiscal year 2023 financial results, highlighted by a $50 million financing and progress in clinical trials for its lead drug candidate, briquilimab.

Jasper Therapeutics has announced the pricing of a $50 million underwritten public offering of common stock to fund its clinical development programs and for general corporate purposes.